[FinancialReports](/) / [Companies](/companies/search/) / [South Korea](/companies/countries/south-korea/) / **000020** ![DONGWHA PHARM.CO.,LTD logo](https://cdn.financialreports.eu/financialreports/media/DONGWHA%20PHARM.CO.%2CLTD/other/DONGWHA_PHARM.CO.LTD-logo.png) # DONGWHA PHARM.CO.,LTD — Investor Relations & Filings Ticker · **000020** ISIN · **KR7000020008** KO Manufacturing [Open in API](/api-solutions/) Overview Filings 224 Market data Peer group API Filings indexed 224 across all filing types Latest filing 2026-05-15 Interim / Quarterly Rep… Country KR South Korea Listing KO 000020 ## About DONGWHA PHARM.CO.,LTD Dongwha Pharm is a pharmaceutical company engaged in the research, development, manufacturing, and sale of a diverse range of healthcare products. Its portfolio includes ethical (prescription) pharmaceuticals, over-the-counter (OTC) drugs, medical devices, quasi-drugs, health functional foods, cosmetics, and beverages. The company's research and development efforts focus on various therapeutic areas, including alimentary and cardiovascular systems. Dongwha Pharm actively pursues innovation through its drug pipeline, clinical trials, and strategic investments in emerging fields like digital therapeutics. ## Recent filings View all 224 → | Filing | Released | Lang | Actions | | --- | --- | --- | --- | | [**분기보고서 (2026.03)**](/filings/dongwha-pharmcoltd/interim-quarterly-report/2026/46361849/) Interim / Quarterly Report Classification · 90% confidence The document is a comprehensive quarterly report (“분기보고서”) covering the 98th fiscal term (2026-01-01 to 2026-03-31) with detailed financial statements, segment reporting, business overview, capital changes, and subsidiary information. It is not a brief announcement or certification but the full interim financial report itself, matching the definition of an Interim/Quarterly Report (IR). · Q1 2026 | 2026-05-15 | Korean | | | [**공정거래자율준수프로그램운영현황(안내공시)**](/filings/dongwha-pharmcoltd/regulatory-filings/2026/38406402/) Regulatory Filings Classification · 80% confidence The document is a Korean regulatory disclosure titled “공정거래 자율준수프로그램 운영현황(안내공시)” which outlines the Compliance Program (CP) Q1 2026 performance and Q2 2026 plan. It is not an earnings announcement, financial report, proxy statement, or executive change notice. It provides operational details of a compliance program as a statutory announcement. There is no indication it is an investor presentation or report publication notice; rather, it is the substantive disclosure itself. Since it does not fit any specialized category, it falls under the fallback Regulatory Filings category. | 2026-04-29 | Korean | | | [**사외이사의선임ㆍ해임또는중도퇴임에관한신고**](/filings/dongwha-pharmcoltd/boardmanagement-information/2026/33047881/) Board/Management Information Classification · 88% confidence The document is a regulatory submission to the Financial Supervisory Service/KRX detailing the appointment of outside directors (사외이사 신규선임) for Donghwa Pharmaceutical Co., Ltd., including names, birth dates, appointment dates, and career backgrounds. This is an announcement of changes in the company’s board of directors. It matches the “Board/Management Information” category. | 2026-03-26 | Korean | | | [**정기주주총회결과**](/filings/dongwha-pharmcoltd/declaration-of-voting-results-voting-rights-announcements/2026/33047833/) Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document text is a detailed report of an Annual General Meeting (AGM) held on 2026-03-26. It lists the approval of financial statements, dividend resolution, election of directors and auditors, meeting date, record date, and voting results for each agenda item (e.g., approval rates, resolutions passed). This corresponds precisely to Declaration of Voting Results & Voting Rights Announcements. Hence, the correct classification is DVA. | 2026-03-26 | Korean | | | [**사업보고서 (2025.12)**](/filings/dongwha-pharmcoltd/annual-report/2026/32971252/) Annual Report Classification · 100% confidence The document is a formal 'Independent Auditor's Report' (감사보고서) for Dongwha Pharm Co., Ltd., covering the fiscal years 2024 and 2025. It includes the auditor's opinion, key audit matters, and the full set of consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, and Statement of Cash Flows) along with detailed notes. Since this is a comprehensive annual financial report containing audited financial statements, it is classified as an Annual Report (10-K). · FY 2025 | 2026-03-18 | Korean | | | [**감사보고서제출**](/filings/dongwha-pharmcoltd/audit-report-information/2026/32971229/) Audit Report / Information Classification · 96% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Dongwha Pharm. It provides a summary of the audit opinion (unqualified/appropriate) and key financial data (assets, liabilities, equity, revenue, profit) for both consolidated and separate financial statements. While it contains financial data, it is a standard regulatory disclosure form used in the Korean market to announce the receipt and submission of the audit report to the exchange, rather than the full annual report document itself. Therefore, it is classified as an Audit Report/Information filing. · FY 2025 | 2026-03-18 | Korean | | ## Browse filings by year 9 years - [2026 18 filings](/companies/dongwha-pharmcoltd/2026/) - [2025 31 filings](/companies/dongwha-pharmcoltd/2025/) - [2024 26 filings](/companies/dongwha-pharmcoltd/2024/) - [2023 24 filings](/companies/dongwha-pharmcoltd/2023/) - [2022 31 filings](/companies/dongwha-pharmcoltd/2022/) - [2021 21 filings](/companies/dongwha-pharmcoltd/2021/) - [2020 49 filings](/companies/dongwha-pharmcoltd/2020/) - [2019 21 filings](/companies/dongwha-pharmcoltd/2019/) - [2018 3 filings](/companies/dongwha-pharmcoltd/2018/) [["13", "AGM Information"], ["1", "Annual Report"], ["53", "Audit Report / Information"], ["47", "Board/Management Information"], ["48", "Capital/Financing Update"], ["22", "Declaration of Voting Results & Voting Rights Announcements"], ["20", "Director's Dealing"], ["6", "Earnings Release"], ["10", "Environmental & Social Information"], ["11", "Governance Information"], ["19", "Interim / Quarterly Report"], ["23", "M&A Activity"], ["24", "Major Shareholding Notification"], ["45", "Notice of Dividend Amount"], ["46", "Proxy Solicitation & Information Statement"], ["18", "Regulatory Filings"], ["51", "Share Issue/Capital Change"], ["52", "Transaction in Own Shares"]] [["100", "Korean"]] Financial Reporting & Info Annual General Meeting Debt Information ESG Information Equity Information M&A, Partnerships & Legal Management & Remuneration Other Filing type Language Start date End date Apply filters [Clear](/companies/dongwha-pharmcoltd/) Report missing filing Download originals Download Markdown | | ID | Filing | Released | Lang | Actions | | --- | --- | --- | --- | --- | --- | | [2026](/companies/dongwha-pharmcoltd/2026/) 15 filings | | | | | | | | 46361849 | [**분기보고서 (2026.03)**](/filings/dongwha-pharmcoltd/interim-quarterly-report/2026/46361849/) Interim / Quarterly Report Classification · 90% confidence The document is a comprehensive quarterly report (“분기보고서”) covering the 98th fiscal term (2026-01-01 to 2026-03-31) with detailed financial statements, segment reporting, business overview, capital changes, and subsidiary information. It is not a brief announcement or certification but the full interim financial report itself, matching the definition of an Interim/Quarterly Report (IR). · Q1 2026 | 2026-05-15 | Korean | | | | 38406402 | [**공정거래자율준수프로그램운영현황(안내공시)**](/filings/dongwha-pharmcoltd/regulatory-filings/2026/38406402/) Regulatory Filings Classification · 80% confidence The document is a Korean regulatory disclosure titled “공정거래 자율준수프로그램 운영현황(안내공시)” which outlines the Compliance Program (CP) Q1 2026 performance and Q2 2026 plan. It is not an earnings announcement, financial report, proxy statement, or executive change notice. It provides operational details of a compliance program as a statutory announcement. There is no indication it is an investor presentation or report publication notice; rather, it is the substantive disclosure itself. Since it does not fit any specialized category, it falls under the fallback Regulatory Filings category. | 2026-04-29 | Korean | | | | 33047881 | [**사외이사의선임ㆍ해임또는중도퇴임에관한신고**](/filings/dongwha-pharmcoltd/boardmanagement-information/2026/33047881/) Board/Management Information Classification · 88% confidence The document is a regulatory submission to the Financial Supervisory Service/KRX detailing the appointment of outside directors (사외이사 신규선임) for Donghwa Pharmaceutical Co., Ltd., including names, birth dates, appointment dates, and career backgrounds. This is an announcement of changes in the company’s board of directors. It matches the “Board/Management Information” category. | 2026-03-26 | Korean | | | | 33047833 | [**정기주주총회결과**](/filings/dongwha-pharmcoltd/declaration-of-voting-results-voting-rights-announcements/2026/33047833/) Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document text is a detailed report of an Annual General Meeting (AGM) held on 2026-03-26. It lists the approval of financial statements, dividend resolution, election of directors and auditors, meeting date, record date, and voting results for each agenda item (e.g., approval rates, resolutions passed). This corresponds precisely to Declaration of Voting Results & Voting Rights Announcements. Hence, the correct classification is DVA. | 2026-03-26 | Korean | | | | 32971252 | [**사업보고서 (2025.12)**](/filings/dongwha-pharmcoltd/annual-report/2026/32971252/) Annual Report Classification · 100% confidence The document is a formal 'Independent Auditor's Report' (감사보고서) for Dongwha Pharm Co., Ltd., covering the fiscal years 2024 and 2025. It includes the auditor's opinion, key audit matters, and the full set of consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, and Statement of Cash Flows) along with detailed notes. Since this is a comprehensive annual financial report containing audited financial statements, it is classified as an Annual Report (10-K). · FY 2025 | 2026-03-18 | Korean | | | | 32971229 | [**감사보고서제출**](/filings/dongwha-pharmcoltd/audit-report-information/2026/32971229/) Audit Report / Information Classification · 96% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Dongwha Pharm. It provides a summary of the audit opinion (unqualified/appropriate) and key financial data (assets, liabilities, equity, revenue, profit) for both consolidated and separate financial statements. While it contains financial data, it is a standard regulatory disclosure form used in the Korean market to announce the receipt and submission of the audit report to the exchange, rather than the full annual report document itself. Therefore, it is classified as an Audit Report/Information filing. · FY 2025 | 2026-03-18 | Korean | | | | 32926197 | [**[기재정정]주주총회소집공고**](/filings/dongwha-pharmcoltd/agm-information/2026/32926197/) AGM Information Classification · 95% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Dong-A Pharmaceutical. It contains the agenda for the 97th Annual General Meeting, including reports on financial statements, board appointments, and governance matters. While it contains financial data, it is a formal proxy solicitation and meeting notice document sent to shareholders to inform them of the meeting details and voting agenda, which fits the definition of a Proxy Solicitation & Information Statement. | 2026-03-11 | Korean | | | | 32926185 | [**의결권대리행사권유참고서류**](/filings/dongwha-pharmcoltd/proxy-solicitation-information-statement/2026/32926185/) Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (DART system) used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains the meeting agenda, proxy solicitation details, and financial statements (balance sheet, income statement, etc.) as required by law for shareholders to make informed voting decisions. This fits the definition of a Proxy Solicitation & Information Statement (PSI). | 2026-03-11 | Korean | | | | 32926126 | [**주주총회소집공고**](/filings/dongwha-pharmcoltd/proxy-solicitation-information-statement/2026/32926126/) Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Dong-Wha Pharmaceutical. It contains the meeting agenda, details on voting procedures (including electronic voting), and management information such as director candidates and financial statements for the 97th fiscal year. This type of document is a standard proxy solicitation and information statement provided to shareholders prior to an AGM to inform them of the meeting and request their votes. | 2026-03-11 | Korean | | | | 32920543 | [**[기재정정]주주총회소집결의**](/filings/dongwha-pharmcoltd/proxy-solicitation-information-statement/2026/32920543/) Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal regulatory filing titled '주주총회소집결의' (Resolution for Convening a General Meeting of Shareholders) and is marked as a '정정신고' (Correction Report). It details the agenda for an upcoming Annual General Meeting (AGM), including the appointment of directors, auditors, and financial statement approval. Since this document provides the specific agenda and details for the meeting rather than just announcing the publication of a report, it falls under the category of Proxy Solicitation & Information Statement (PSI), which is the standard classification for materials requesting shareholder votes and providing meeting details. | 2026-03-10 | Korean | | | | 32916676 | [**최대주주등소유주식변동신고서**](/filings/dongwha-pharmcoltd/directors-dealing/2026/32916676/) Director's Dealing Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders and Related Parties' (최대주주등소유주식변동신고서) filed by Dongwha Pharm. It details specific share transactions (purchases) made by a related party (Yoon Hyun-ho) and provides a comprehensive table of the total shareholding status of the major shareholders and related entities. This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions by individuals associated with the company's leadership/major shareholder group. | 2026-03-09 | Korean | | | | 32834035 | [**매출액또는손익구조30%(대규모법인은15%)이상변경**](/filings/dongwha-pharmcoltd/earnings-release/2026/32834035/) Earnings Release Classification · 95% confidence The document is a regulatory filing from Dongwha Pharm regarding a significant change in sales or profit/loss structure (30% or more). This is a standard financial disclosure required by the Korea Exchange (KRX) when a company's financial performance deviates significantly from the previous year. It provides preliminary financial data (sales, operating profit, net income) for the fiscal year 2025 compared to 2024. Since it is an initial announcement of financial results (key highlights) rather than a full annual report or a transcript, it falls under the 'Earnings Release' category. · FY 2025 | 2026-02-24 | Korean | | | | 32834003 | [**[기재정정]현금ㆍ현물배당결정**](/filings/dongwha-pharmcoltd/notice-of-dividend-amount/2026/32834003/) Notice of Dividend Amount Classification · 100% confidence The document is a formal regulatory filing from Dongwha Pharm regarding a correction to a previously announced cash dividend decision. It specifies the dividend amount per share, the dividend yield, the record date, and the date of the upcoming general meeting of shareholders. Since the primary purpose of the document is to announce the details of a dividend payment, it falls under the 'Notice of Dividend Amount' category. | 2026-02-24 | Korean | | | | 32833507 | [**주주총회소집결의**](/filings/dongwha-pharmcoltd/proxy-solicitation-information-statement/2026/32833507/) Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of an Annual General Meeting (AGM) for Dongwha Pharm, detailing the date, location, and agenda items such as financial statement approval, board appointments, and remuneration limits. This is a standard proxy solicitation document sent to shareholders to inform them of the upcoming meeting and request their votes on the listed agenda items. | 2026-02-24 | Korean | | | | 32832832 | [**현금ㆍ현물배당결정**](/filings/dongwha-pharmcoltd/notice-of-dividend-amount/2026/32832832/) Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Dongwha Pharm regarding a decision on cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the date of the upcoming general meeting of shareholders. This fits the definition of a 'Notice of Dividend Amount' (DIV). | 2026-02-24 | Korean | | Page **1** of **15** 1 [2](?page=2#filings) [3](?page=3#filings) … [Next](?page=2#filings) ## Market data ### Market data not available Last price Market cap volume Day range today 52-week range trailing ### Price history 1Y 5Y 10Y ## Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products 2,202 peers | Company | Ticker | Country | Sector | | --- | --- | --- | --- | | [**13260917 Canada Inc.**](/companies/13260917-canada-inc/) Biotech developing oral small molecules to restore muscle s… | MSCL | CA | Manufacturing | | [**1608557 Ontario Inc.**](/companies/1608557-ontario-inc/) Biopharmaceutical company dedicated to R&D, discovery, and … | OTROQ | CA | Manufacturing | | [**3B BlackBio Dx Limited**](/companies/3b-blackbio-dx-limited/) Develops molecular diagnostic kits for oncology, infectious… | 3BBLACKBIO | IN | Manufacturing | | [**3D Medicines Inc.**](/companies/3d-medicines-inc/) Commercial-stage biopharma specializing in next-generation … | 1244 | HK | Manufacturing | | [**3SBio Inc.**](/companies/3sbio-inc/) Biopharmaceutical enterprise specializing in R&D, productio… | 1530 | KY | Manufacturing | | [**4BASEBIO PLC**](/companies/4basebio-plc/) Manufactures GMP-grade synthetic DNA for next-generation th… | 4BB | GB | Manufacturing | | [**4D Molecular Therapeutics, Inc.**](/companies/4d-molecular-therapeutics-inc/) Develops genetic medicines using AAV vectors for ophthalmol… | FDMT | US | Manufacturing | | [**4Front Ventures Corp.**](/companies/4front-ventures-corp/) Vertically integrated cannabis operator managing cultivatio… | FFNT | CA | Manufacturing | | [**4SC AG**](/companies/4sc-ag/) Biopharmaceutical company with no products under developmen… | VSC | DE | Manufacturing | | [**60 DEGREES PHARMACEUTICALS, INC.**](/companies/60-degrees-pharmaceuticals-inc/) Develops and commercializes medicines for infectious diseas… | SXTP | US | Manufacturing | Page **1** of **221** 1 [2](?peer_page=2#peers) [3](?peer_page=3#peers) … [Next](?peer_page=2#peers) ### DONGWHA PHARM.CO.,LTD via the API Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec. [Get API access](/api-solutions/) [Read API reference](/developers/reference/) Base URLapi.financialreports.eu Auth headerx-api-key Company ID17346 Ticker000020 ISINKR7000020008 ### Endpoints most-used routes for this company | | | | | --- | --- | --- | | GET | /api/companies/17346/ | Company identity, sector, listing, identifiers | | GET | /api/filings/?company=17346 | Paginated list of all filings (filterable by type, date, language) | | GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status | | GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) | | GET | /api/isins/?company=17346 | All ISINs registered to this company | | GET | /api/filing-types/ | Reference: every filing-type code + category | Full reference: [API reference](/developers/reference/) · [OpenAPI schema](/api/schema/) ### cURL latest filings for DONGWHA PHARM.CO.,LTD ``` $ curl https://api.financialreports.eu/api/filings/?company=17346 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json" ``` ### Python requests ``` import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 17346}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"] ``` ### MCP server Claude · Claude Code · ChatGPT [Claude setup →](/integrations/claude/) [ChatGPT setup →](/integrations/chatgpt/) [Claude Code setup →](/integrations/claude-code/) ``` // MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for DONGWHA PHARM.CO.,LTD (id: 17346)" ``` #### AI · Markdown Filings as Markdown Drop the latest filing into Claude or ChatGPT, or query via MCP from your client. [Open Markdown↗](/filings/dongwha-pharmcoltd/interim-quarterly-report/2026/46361849/) [Open in MCP↗](/integrations/claude/) [cURL endpoint$](/api-solutions/) #### Identity Legal nameDONGWHA PHARM.CO.,LTD HQ중구, KR ListingKO ISINKR7000020008 Sector[Manufacturing](/companies/sectors/manufacturing/) Industry[Manufacture of pharmaceuticals, medicinal chemical and botanical products](/companies/sectors/manufacturing/manufacture-of-pharmaceuticals-medicinal-chemical-and-botanical-products/) #### Coverage Filings indexed 224 Next annual report Mar 13–Mar 25, 2027 Confidence 100% ### Report missing filing Can't find a specific document? Let us know and we'll add it within 24 hours. What is missing or wrong? Your email We will notify you once the filing is added. Cancel Send report Sending… Report sent Thank you. We will check the data and update it shortly. × (function() { const tabs = document.querySelectorAll('.cmp-tabs-wrap .fr-tab'); const panes = document.querySelectorAll('.tab-pane'); function activate(target, pushHash) { tabs.forEach(t => { const isActive = t.dataset.tab === target; t.classList.toggle('fr-tab--active', isActive); t.setAttribute('aria-selected', isActive ? 'true' : 'false'); }); panes.forEach(p => { const isActive = p.dataset.pane === target; p.classList.toggle('tab-pane--active', isActive); p.hidden = !isActive; }); if (pushHash) { try { history.replaceState(null, '', '#' + target); } catch (e) {} } } tabs.forEach(tab => { tab.addEventListener('click', () => { activate(tab.dataset.tab, true); window.scrollTo({ top: 0, behavior: 'instant' }); }); }); const initial = (window.location.hash || '').replace('#', ''); const validTabs = ['overview', 'filings', 'financials', 'market', 'peers', 'api']; const legacyMap = { 'market-data': 'market', 'peer-group': 'peers' }; let target = legacyMap[initial] || (validTabs.indexOf(initial) >= 0 ? initial : 'overview'); if (target !== 'overview') activate(target, false); })();